| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3334995 | Transfusion and Apheresis Science | 2014 | 10 Pages |
Abstract
The objectives of this study were to evaluate the cost-effectiveness and budget impact of octaplasLG® compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion in Canada. A decision analytic framework was used to model acute and long-term complications that could follow plasma transfusion. Over a life time horizon, the cost with octaplasLG® were CA$612.91, which is CA$303.14 less than those with FFP. OctaplasLG® resulted in 0.021 quality adjusted life years (QALYs) gained in comparison with FFP. Because of higher efficacy and lower costs, octaplasLG® is expected to be the dominant treatment option over FFP in Canada.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Eline L. Huisman, Margreet C. van Eerd, J.N. Mario Ouwens, Maria A. de Peuter,